Takeda Pharmaceutical company is accelerating a sweeping overhaul of its operations as layoffs continue to mount across its U.S. business, underscoring a broader effort to streamline costs and refocus on future growth.

Recent filings and industry reports indicate that more than 600 U.S. employees could be affected by the latest restructuring wave, with cuts spanning multiple functions and locations. A significant portion of the reductions are tied to the company’s presence in Cambridge, Massachusetts, while earlier rounds of layoffs have impacted commercial and research roles nationwide.

The restructuring is part of Takeda’s plan to generate roughly $1.3 billion in annual savings by 2028, as the company works to simplify its organizational structure and improve operating efficiency. Executives have framed the changes as necessary to remain competitive amid rising research costs and increasing pressure from generic drug competition.

Much of the workforce reduction reflects a shift away from legacy products and lower-growth segments. The company has already scaled back its neuroscience sales team and exited certain areas such as cell therapy manufacturing, reallocating resources toward high-priority therapeutic areas including rare diseases and plasma-therapy treatments.

The overhaul comes at a pivotal moment for Takeda as it prepares for a leadership transition in 2026 and navigates the loss of exclusivity for key drugs. Like many large pharmaceutical companies, Takeda is balancing near-term cost pressures with the need to invest heavily in its pipeline of new treatments.

While the layoffs represent a significant contraction in some areas, the company has signaled it will continue hiring in targeted segments tied to upcoming drug launches. The result is less a broad treatment and more a recalibration-one that reflects how major pharmaceutical brands are reshaping their workforce to align with the next generation of therapies.